FIELD: chemistry.
SUBSTANCE: invention relates to 4-[(1S)-1-({[4-bromo-1-(isoquinolin-3-ylmethyl)-3-methyl-1H-pyrazol-5-yl]carbonyl}amino)ethyl]benzoic acid or its pharmaceutically acceptable salt, preferably to the methanesulfonate salt, and most preferably to the crystalline methanesulfonate salt of the above compound. This invention provides a compound that has an antagonistic effect on the EP4 receptor.
EFFECT: this compound and its pharmaceutically acceptable salts can be used as the active ingredient of the pharmaceutical composition for prevention and / or treatment of various diseases associated with EP-4, for example chronic renal failure and / or diabetic nephropathy.
11 cl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW EP4 AGONIST | 2011 |
|
RU2564414C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2762193C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2717331C2 |
| 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | 2014 |
|
RU2662806C2 |
| DERIVATIVES OF PROSTAGLANDINS WITHOUT ADVERSE EFFECTS FOR GLAUCOMA TREATMENT | 1998 |
|
RU2207858C2 |
| NITROGEN-CONTAINING 6-ELEMENT CYCLIC COMPOUNDS | 2018 |
|
RU2772958C2 |
| PROSTAMIDES AND THEIR ANALOGUES POSSESSING NEUROPROTECTIVE ACTION | 2011 |
|
RU2474426C1 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2606510C2 |
| AMIDE COMPOUND | 2009 |
|
RU2479576C9 |
